A case of paliperidone-palmitate-induced tardive dyskinesia

Lally, John; Byrne, Fintan; Walsh, Elizabeth

doi:10.1016/j.genhosppsych.2012.04.009

Cited by 7 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its adverse effect profile is similar to that of the parent compound risperidone, with increased weight gain, hyperprolactinaemia and EPSEs at higher doses, along with case reports of tardive dyskinesia. 38 At doses of 9-12 mg of oral paliperidone (equivalent to risperidone 4-6 mg daily), the risk of EPSEs is increased. The therapeutic dose range is 6-9 mg once daily (equivalent to risperidone 3-4 mg daily).…”

Section: Paliperidonementioning

confidence: 99%

Antipsychotic medication in schizophrenia: a review

2015

Self Cite

View full text Add to dashboard Cite

A focus on the different symptom domains of schizophrenia may lead to endophenotypic markers being identified, e.g. for negative symptoms and cognitive deficits (as well as for positive symptoms) that can promote the development of novel therapeutics, which will rationally target cellular and molecular targets, rather than just the dopamine 2 receptor. Future developments will target additional processes, including glutamatergic, cholinergic and cannabinoid receptor targets and will utilize personalized medicine techniques, such as pharmacogenetic variants and biomarkers allowing for a tailored and safer use of antipsychotics.

show abstract

Section: Paliperidonementioning

confidence: 99%

Antipsychotic medication in schizophrenia: a review

2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, we are basically dealing with an olanzapine overdose. No such syndrome has been reported in paliperidone palmitate so far, although cases of tardive dyskinesia, catatonia and encephalopathy have been found (Coffey, 2012;Lally et al, 2013). In our report we present a case study of a patient treated by paliperidone palmitate with an occurrence of severe acute dystonia/akathisia, which could be caused by rapid release of paliperidone to the blood stream.…”

mentioning

confidence: 73%

Severe acute dystonia/akathisia after paliperidone palmitate application – a case study

Ustohal¹,

Přikryl²,

Hublová³

et al. 2013

Int. J. Neuropsychopharm.

View full text Add to dashboard Cite

“…8 Lally et al have also reported a patient with paranoid schizophrenia who developed orofacial TD after 4-month treatment with paliperidone palmitate. 9 Also, the occurrence of TD in association with oral paliperidone has been reported in a small number of case reports. 10,11 Several demographic and clinical factors are known to increase the risk of TD.…”

Section: Discussionmentioning

confidence: 99%